[go: up one dir, main page]

AU2001252964A1 - Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders - Google Patents

Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders

Info

Publication number
AU2001252964A1
AU2001252964A1 AU2001252964A AU5296401A AU2001252964A1 AU 2001252964 A1 AU2001252964 A1 AU 2001252964A1 AU 2001252964 A AU2001252964 A AU 2001252964A AU 5296401 A AU5296401 A AU 5296401A AU 2001252964 A1 AU2001252964 A1 AU 2001252964A1
Authority
AU
Australia
Prior art keywords
inflammatory
rna
yeast
treatment
related disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001252964A
Inventor
Zenoviy Tkachuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocell Laboratories Inc
Original Assignee
Biocell Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocell Laboratories Inc filed Critical Biocell Laboratories Inc
Publication of AU2001252964A1 publication Critical patent/AU2001252964A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention concerns a compound consisting of RNA, in particular RNA extracted from yeast, a pharmaceutical composition comprising such RNA and a method for the treatment of inflammatory and inflammatory-related disorders comprising administering to a patient in need of such torment a pharmaceutical composition comprising an amount effective to ameliorate the symptoms of inflammation or inflammatory-related disorder of ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent. The exogenous yeast RNA used in the present invention has a pronounced membrane-stabilizing action in a wide range of concentrations. At the same time, yeast RNA normalizes metabolism of arachidonic acid and levels of its key metabolites, thromboxane and leukotriene. Its anti-inflammatory action is accompanied by normalization of the activity of NO-synthetase and anti-oxidant activity.
AU2001252964A 2000-03-24 2001-03-26 Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders Abandoned AU2001252964A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09534509 2000-03-24
US09/534,509 US6737271B1 (en) 2000-03-24 2000-03-24 Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders
PCT/US2001/009590 WO2001073003A1 (en) 2000-03-24 2001-03-26 Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders

Publications (1)

Publication Number Publication Date
AU2001252964A1 true AU2001252964A1 (en) 2001-10-08

Family

ID=24130363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001252964A Abandoned AU2001252964A1 (en) 2000-03-24 2001-03-26 Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders

Country Status (9)

Country Link
US (1) US6737271B1 (en)
EP (1) EP1278836B1 (en)
CN (1) CN1451041B (en)
AT (1) ATE465254T1 (en)
AU (1) AU2001252964A1 (en)
DE (1) DE60141898D1 (en)
EA (1) EA010182B1 (en)
UA (1) UA66416C2 (en)
WO (1) WO2001073003A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153839B2 (en) * 2000-03-24 2006-12-26 Biocell Laboratories Method of protecting erythricytes, in particular for improvement of blood cytopenia
DE10309368A1 (en) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmaceutical preparation with RNA as a cofactor of hemostasis
DE10242016A1 (en) * 2002-09-11 2004-03-25 Esplora GmbH c/o TU Darmstadt Institut für Biochemie Identifying blood-brain barrier protein, useful e.g. as drug transporter and for treatment or diagnosis, by subtractive hybridization using cDNA from brain capillary cells
IT1391866B1 (en) 2008-10-30 2012-01-27 Mastelli S R L INJECTIONABLE COMPOSITION OF POLYNUCLEOTIDS FOR THE TREATMENT OF OSTEOARTICULAR DISEASES.
US8420617B2 (en) 2011-03-11 2013-04-16 Biocell Laboratories Multiantivirus compound, composition and method for treatment of virus diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615654A (en) * 1968-05-17 1971-10-26 Cpc International Inc Method of treating microbial cells
US3914450A (en) * 1973-04-09 1975-10-21 Anheuser Busch Concentrated extract of yeast and processes of making same
EP0654077A4 (en) * 1992-07-17 1996-03-13 Ribozyme Pharm Inc Method and reagent for treatment of animal diseases.
WO1995001097A1 (en) 1993-06-30 1995-01-12 Board Of Regents, The University Of Texas System Nucleotide preparation and uses thereof in wound healing

Also Published As

Publication number Publication date
EP1278836B1 (en) 2010-04-21
UA66416C2 (en) 2004-05-17
DE60141898D1 (en) 2010-06-02
CN1451041A (en) 2003-10-22
EA200201015A1 (en) 2003-06-26
US6737271B1 (en) 2004-05-18
WO2001073003A1 (en) 2001-10-04
CN1451041B (en) 2010-06-16
ATE465254T1 (en) 2010-05-15
EP1278836A4 (en) 2004-07-07
EA010182B1 (en) 2008-06-30
EP1278836A1 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
CA2191129C (en) Drugs containing metronidazole or a synergistic mixture of metronidazole and clindamycin
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CA2209167A1 (en) Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
Yamamoto et al. Topical tacrolimus is effective for facial lesions of psoriasis
WO1995018622A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
HUP9902103A2 (en) Triaryl compounds
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
IL122401A0 (en) Anti-inflammatory compositions
MEP54608A (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2005049827B1 (en) Ppmp as a ceramide catabolism inhibitor for cancer treatment
AU2001252964A1 (en) Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders
Scherbel III. The effect of isoniazid and of iproniazid in patients with rheumatoid arthritis
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
BR9911598A (en) Use of derivatives of 2-hydroxy-4-trifluoromethylbenzoic acid as inhibitors of activation of the nuclear transcription factor nf-kb
MY103734A (en) Methods and compositions for the treatment of psoriasis
AT509045B1 (en) COMPOUNDS FOR THE TREATMENT OF ASTHMA BRONCHIALE
Sehgal et al. Antifungal agents: unapproved uses, dosages, or indications
WO2000003703A1 (en) Novel remedies for allergic diseases
WO2000067732A3 (en) Pharmaceutical composition, containing an antimycotic, polydocanol and salicylic acid
US20040023937A1 (en) Anti-cancer formulation
US4663345A (en) Etodolac for treatment of gout
FR2897534A1 (en) USE OF TESAGLITAZAR FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
EP2123265B1 (en) Endipalene formulations in the treatment of psoriasis
WO2001001995A3 (en) Method for treatment of asthma syndrome